Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Ongoing Research to Watch in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Additional Potential Roles for Mirvatuximab Soravtansine and Other ADCs in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

PICCOLO Data for Mirvatuximab Soravtansine in FRα+, Platinum-Sensitive Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer

Testing for FRα in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.

How Mirvatuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer

February 6th 2025

Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.

Current Treatment Considerations for Platinum-Resistant Ovarian Cancer

February 6th 2025

Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer

February 5th 2025

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer

February 1st 2025

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?

January 31st 2025

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer

January 31st 2025

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

Dr Lheureux on the Evolution of ADCs Since Mirvetuximab Soravtansine in Ovarian Cancer

January 31st 2025

Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer

January 31st 2025

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer

January 30th 2025

Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

Olaparib Elicits Improved OS Rates in Platinum-Sensitive, Germline/Somatic BRCA+ Relapsed Ovarian Cancer

January 29th 2025

A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA mutations.

Azenosertib Monotherapy Appears Safe and Effective in Ovarian Cancer

January 29th 2025

Azenosertib (ZN-c3) monotherapy was active in heavily pretreated patients with cyclin E1–positive platinum-resistant ovarian cancer.

Dr Hinchcliff on the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 25th 2025

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Dr Hayek on the Rationale of Assessing Laparoscopic Surgery in Advanced Ovarian Cancer

January 22nd 2025

Judy Hayek, MD, explains the rationale of a retrospective analysis evaluating laparoscopic vs open surgery in advanced ovarian cancer.

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer

January 17th 2025

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Dr Goldsberry on PARP Inhibitor Selection in Advanced Ovarian Cancer

January 9th 2025

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Dr Nasioudis on the Potential for XPO1 Inhibition in TP53 Wild-Type Ovarian Cancer

January 8th 2025

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.